IPO Calendar 18 FEB
List of companies going public this week.
Feb 19
Anbio Biotechnology (NNNN)
IPO Price Range $5.00 - $6.00
Shares Offered 1,600,000
Deal Size $8.80M
Market Cap 241.40M
Revenue (ttm) 9.50M
Net Income (ttm) 4.33M
Company Description
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs. Our comprehensive range encompasses solutions for various applications, including over-the-counter utilization, point-of-care settings, and laboratory applications. Our IVD products are designed to detect a wide range of biomarkers associated with critical medical domains. These domains encompass infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes.
Review the financial statements
Feb 20
Danam Health, Inc. (WGRX)
IPO Price Range $4.50 - $5.50
Shares Offered 900,000
Deal Size $4.50M
Market Cap 259.78M
Revenue (ttm) 52.75M
Net Income (ttm) -16.90M
Company Description
Danam Health, Inc. is a holding company for various existing and planned strategic businesses centered around pharmaceuticals and healthcare services.
As a micro health ecosystem, our portfolio of companies consists of a pharmacy, wholesale operations, and a technology division with a novel platform for hub and clinical services.
We are focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.
Review the financial statements
Feb 21
Apimeds Pharmaceuticals US, Inc. (APUS)
IPO Price Range $4.00 - $5.00
Shares Offered 4,500,000
Deal Size $20.25M
Market Cap 57.12M
Revenue (ttm) n/a
Net Income (ttm) -1.42M
Company Description
Apimeds Pharmaceuticals US is a clinical stage biopharmaceutical company that is in the process of developing Apitox, an intradermally administered bee venom-based toxin which potentially exhibits diverse therapeutic effects.
Apimeds is currently developing Apitox as a potential osteoarthritis treatment for patients with knee pain who failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics.
Apitoxin has been used in the South Korea to treat the reduction of pain associated with OA since 2003 and now we will be pursuing a second Phase III trial to meet agreed upon FDA standards.
Upon the successful completion of our Phase III trial demonstrating therapeutic effect and extended safety data for the use of Apitox to treat pain and mobility in patients with knee OA, we intend to submit a Biologics License Application for Apitox.
Review the financial statements